Cancer Chemo- and Immunopharmacology: 2: Immunopharmacology, Relations, and General Problems

Front Matter....Pages I-XI
Tumor-Specific Antigens....Pages 1-9
Autoreactive Cells as Mediators of the Natural Defense Against Malignant Tumors....Pages 10-15
Progress in Experimental Systemic Active Immunotherapy of Cancer....Pages 16-19
Host’s Immune State and Kinetics of Local Tumor Growth Control — Progression of Postoperative Lung Metastasis....Pages 20-28
Immunotherapy Versus Chemotherapy of Acute Myeloid Leukemia: Response to PHA, Allogeneic Lymphocytes, and Leukemic Myeloblasts of Remission Lymphocytes from Leukemia Patients....Pages 29-36
Suppressor Cells in Hodgkin’s Disease and Lung Carcinoma....Pages 37-40
Immune Imbalance in Cancer Patients....Pages 41-46
Immunorestoration of Anergic Cancer Patients by Azimexon....Pages 47-52
BCG Versus VCN: The Antigenicity and the Adjuvant Effect of Both Compounds....Pages 53-60
Differences in Chemotherapeutic Susceptibility of Human T-, B-, and Non-T-/Non-B-Lymphocytes in Culture....Pages 61-67
The Significance of Lectin Receptors in the Kidney and in Hypernephroma (Renal Adenocarcinoma)....Pages 68-75
Specific Immunotherapy of Acute Lymphoid Leukemia Patients by REH Cell Line....Pages 76-79
Results of Postoperative Treatment of Colorectal Cancer by Radiotherapy, Chemotherapy and Immunotherapy....Pages 80-87
Some “Pharmacologic” Data About Corynebacterium Parvum....Pages 88-91
Increased Resistance to Tumor Graft in Mice Infected by Vaccinal Strains of Brucella Abortus....Pages 92-99
Thymosin: Basic Properties and Clinical Application in the Treatment of Immunodeficiency Diseases and Cancer....Pages 100-105
One or Several Thymic Hormones?....Pages 106-109
Ability of Thymosin to Decrease in Vivo and in Vitro Suppressor Cell Activity in Tumor Bearing Mice and Cancer Patients....Pages 110-114
Screening of Small Molecular Microbial Products Modulating Immune Responses and Bestatin....Pages 115-125
A Review of Clinical Studies of Bestatin....Pages 126-132
Bestatin Treatment and the Peripheral Lymphocyte Population in Cancer Patients....Pages 133-138
Correction of Immunodeficiency in Aged Mice by Levamisole and Bestatin Administration....Pages 139-146
Therapeutic Effects of BM 12,531 (Prop. INN Azimexon)....Pages 147-152
In Vivo Immunomodulating Properties of Two Synthetic Agents: Azimexon and Tuftsin....Pages 153-161
Effects of BM 12,531 (Azimexon) on in Vitro Lymphocyte and Macrophage Proliferation....Pages 162-164
Comparative Evaluation of the Tumor Inhibitory and Antibacterial Activity of Solubilized and Particulate Glucan....Pages 165-172
Mechanism of the Inhibitory Effect of Levan on Experimental Tumors....Pages 173-179
Lynestrenol: A Progesteronelike Agent with Immunostimulatory Properties....Pages 180-184
Chemotherapy Immunogenicity....Pages 185-194
Selective Imbalances of Cellular Immune Responses by Adriamycin....Pages 195-199
The Heterogeneity of the Interaction Between Cancer Chemotherapeutic Agents and Host Resistance Mechanisms....Pages 200-206
Endotoxin-Induced Tumor Necrosis Factor....Pages 207-212
Antimicrobial Resistance Enhancing Activity of Tumor Necrosis Serum Factor Induced by Endotoxin in BCG-Treated Mice....Pages 213-219
Tumor-Necrotizing Serum Production by Administration of BCG + Pseudomonas: Its Application in Treatment of Fibrosarcoma in Mice....Pages 220-225
Usefulness of the Results of Studies on the Antitumor Effects of Interferon in Animals to Interferontherapy of Patients....Pages 226-228
DNA, Liposomes, and Proteins as Carriers for Antitumoral Drugs....Pages 229-235
Antibodies as Carriers for Oncostatic Materials....Pages 236-245
Pulmonary Localization of Intravenously Injected Liposomes....Pages 246-251
Erythrocytes and Lymphocytes as Drug Carrier Systems: Techniques for Entrapment of Drugs in Living Cells....Pages 252-259
Chemo- and Immunopharmacology: The Reality and the Horizons of Cancer Treatment....Pages 260-260
Back Matter....Pages 261-262